Patient Demographics and Prognostic Factors of Skin Appendage Carcinoma: An Analysis of the NCDB
Main Article Content
Keywords
skin appendage carcinoma, adnexal carcinoma, skin cancer, demographics, mortality
Abstract
Background: Skin appendage carcinoma (SAC) is a rare malignancy with limited literature due to its low prevalence. This study explores demographic and prognostic factors for SAC in the United States.
Methods: Data from the National Cancer Database (NCDB) were analyzed to identify factors affecting SAC mortality. Descriptive statistics and Cox regression analysis were employed.
Results: SAC is slightly more common in males and frequently occurs in the face, scalp, and neck regions. Age and Charlson-Deyo comorbidity scores were significant prognostic factors, with older age and higher scores linked to decreased survival. Private insurance predicted better survival compared to Medicaid, Medicare, or no insurance.
Conclusion: Individualized clinical interventions considering patient age, insurance status, and comorbidities are crucial. SAC does not exhibit disparities in survival based solely on race or socioeconomic status, but equitable access to care is essential for improving outcomes.
References
2. Oyasiji T, Tan W, Kane J, et al. Malignant adnexal tumors of the skin: A single institution experience. World Journal of Surgical Oncology. 2018;16(1). doi:10.1186/s12957-018-1401-y.
3. Lee DA, Grossman ME, Schneiderman P, Celebi JT. Genetics of skin appendage neoplasms and related syndromes. J Med Genet. 2005;42(11):811-819. doi:10.1136/jmg.2004.025577
4. AIRTUM Working Group, Busco S, Buzzoni C, et al. Italian cancer figures--Report 2015: The burden of rare cancers in Italy. Epidemiol Prev. 2016;40(1 Suppl 2):1-120.
5. Blake PW, Bradford PT, Devesa SS, Toro JR. Cutaneous appendageal carcinoma incidence and survival patterns in the United States: a population-based study. Arch Dermatol. 2010;146(6):625-632. doi:10.1001/archdermatol.2010.105
6. Stam H, Lohuis PJFM, Zupan-Kajcovski B, Wouters MWJM, van der Hage JA, Visser O. Increasing incidence and survival of a rare skin cancer in the Netherlands. A population-based study of 2,220 cases of skin adnexal carcinoma. J Surg Oncol. 2013;107(8):822-827.
7. Mallone S, De Vries E, Guzzo M, et al. Descriptive epidemiology of malignant mucosal and uveal melanomas and adnexal skin carcinomas in Europe. Eur J Cancer. 2012;48(8):1167-1175.
8. Stam H, van de Wiel BA, Klop WMC, et al. Skin adnexal carcinoma of the head and neck: a retrospective study in a tertiary referral center. Eur Arch Otorhinolaryngol. 2015;272(4):1001-1010.
9. Ireland AM, Harvey NT, Berry BD, Wood BA. Pediatric cutaneous adnexal tumours: a study of 559 cases. Pathology. 2017;49(1):50-54.
10. Jayalakshmi P, Looi LM. Cutaneous adnexal neoplasms in biopsy specimens processed in the Department of Pathology, University of Malaya. Ann Acad Med Singapore. 1996;25(4):522-525.
11. Stewart AK, Bland KI, McGinnis LS Jr, Morrow M, Eyre HJ. Clinical highlights from the National Cancer Data Base, 2000. CA Cancer J Clin. 2000;50(3):171-183.
12. Menck HR, Cunningham MP, Jessup JM, et al. The growth and maturation of the National Cancer Data Base. Cancer. 1997;80(12):2296-2304.
13. McCabe RM. National Cancer Database: The Past, Present, and Future of the Cancer Registry and Its Efforts to Improve the Quality of Cancer Care. Semin Radiat Oncol. 2019;29(4):323-325.
14. Resneck J Jr, Pletcher MJ, Lozano N. Medicare, Medicaid, and access to dermatologists: the effect of patient insurance on appointment access and wait times. J Am Acad Dermatol. 2004;50(1):85-92.
15. Kaundinya T, Kundu RV, Feinglass J. The epidemiology of skin cancer by UV index: cross-sectional analysis from the 2019 behavioral risk factor surveillance survey. Arch Dermatol Res. 2023;315(3):613-615.
16. Wang LS, Handorf EA, Wu H, Liu JC, Perlis CS, Galloway TJ. Surgery and Adjuvant Radiation for High-risk Skin Adnexal Carcinoma of the Head and Neck. Am J Clin Oncol. 2017;40(4):429-432.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.